[{"address1": "4000 Shoreline Court", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 822 5600", "website": "https://www.kezarlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher J. Kirk Ph.D.", "age": 52, "title": "Co-Founder, CEO & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 644685, "exercisedValue": 0, "unexercisedValue": 5485}, {"maxAge": 1, "name": "Mr. John Franklin Fowler", "age": 52, "title": "Co-Founder & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 539349, "exercisedValue": 0, "unexercisedValue": 2641}, {"maxAge": 1, "name": "Mr. Marc L. Belsky CPA", "age": 69, "title": "CFO & Secretary", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 639413, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack  Taunton Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gitanjali  Jain", "title": "Senior Vice President of Investor Relations & External Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Schiller", "age": 44, "title": "Chief Legal Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joe  Tedrick", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neel K. Anand Ph.D.", "title": "Senior Vice President of Research & Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zung  To", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pattie  Chiang", "title": "Senior VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.87, "open": 5.9351, "dayLow": 5.88, "dayHigh": 6.02, "regularMarketPreviousClose": 5.87, "regularMarketOpen": 5.9351, "regularMarketDayLow": 5.88, "regularMarketDayHigh": 6.02, "beta": 0.186, "forwardPE": -0.6342424, "volume": 34760, "regularMarketVolume": 34760, "averageVolume": 45993, "averageVolume10days": 30210, "averageDailyVolume10Day": 30210, "bid": 4.29, "ask": 7.61, "bidSize": 200, "askSize": 200, "marketCap": 42974736, "fiftyTwoWeekLow": 5.2, "fiftyTwoWeekHigh": 11.4, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 6.5232, "twoHundredDayAverage": 6.80505, "currency": "USD", "enterpriseValue": -88501256, "floatShares": 4552988, "sharesOutstanding": 7296220, "sharesShort": 77734, "sharesShortPriorMonth": 85333, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0107, "heldPercentInsiders": 0.11996, "heldPercentInstitutions": 0.5762, "shortRatio": 2.25, "shortPercentOfFloat": 0.0109, "impliedSharesOutstanding": 7296220, "bookValue": 18.372, "priceToBook": 0.32059655, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -95778000, "trailingEps": -13.12, "forwardEps": -10.47, "lastSplitFactor": "1:10", "lastSplitDate": 1730246400, "enterpriseToEbitda": 0.933, "52WeekChange": -0.2927711, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KZR", "underlyingSymbol": "KZR", "shortName": "Kezar Life Sciences, Inc.", "longName": "Kezar Life Sciences, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a58d540c-0082-3b09-9235-096cecf4e362", "messageBoardId": "finmb_304157325", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.89, "targetHighPrice": 18.0, "targetLowPrice": 9.0, "targetMeanPrice": 13.5, "targetMedianPrice": 13.5, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 148388000, "totalCashPerShare": 20.338, "ebitda": -94901000, "totalDebt": 16912000, "quickRatio": 7.317, "currentRatio": 7.655, "debtToEquity": 12.616, "returnOnAssets": -0.29015, "returnOnEquity": -0.54724, "grossProfits": -72354000, "freeCashflow": -43092124, "operatingCashflow": -76367000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]